

CURRICULUM VITAE

February 1, 2002

I. PERSONAL DATA

Name: Howard James Williams, Jr.

II. EDUCATION

B.A., Medical Biology, University of Utah, Salt Lake City, UT

M.D., University of Utah, Salt Lake City, UT

Internship: Straight Medicine, Duke University Medical Center, Durham, NC,
July 1969 - June 1970

Residencies: Medical Resident, Duke University Medical Center, Durham, NC,
July 1970 - June 1972

Chief Medical Resident, University of Utah Medical Center, Salt
Lake City, UT, July 1972-June 1973

Fellowship: Rheumatology, University of Utah Medical Center, Salt Lake City,
UT, August 1975 - July 1977

PROFESSIONAL EXPERIENCE

Professor of Medicine, Department of Internal Medicine, Division of
Rheumatology, University of Utah, Salt Lake City, UT, 1986 - present

Associate Professor, Department of Internal Medicine, Division of
Rheumatology, University of Utah, Salt Lake City, UT, 1981-1986

Assistant Professor, Department of Internal Medicine, Division of Rheumatology,
University of Utah, Salt Lake City, UT, July 1976 - June 1981

Instructor, Department of Internal Medicine, Division of Rheumatology,
University of Utah, Salt Lake City, UT, August 1975 - June 1976

U.S. Army, Major, Medical Corps, Internal Medicine, Irwin Army Hospital, Ft.
Riley, KS, July 1973 - July 1975

Teaching Assistant in Zoology (Embryology), University of Utah, Salt Lake City,
UT, 1964 - 1965

IV. HONORS

B.S., magna cum laude, University of Utah,

Phi Kappa Phi, University of Utah,

Phi Beta Kappa, Utah Chapter, 1966

Alpha Omega Alpha, Utah Chapter,

Haskel Schiff Housestaff Award, Department of Medicine, Duke University
Medical Center,

Thomas E. & Rebecca D. Jeremy Presidential Endowed Chair for Arthritis
Research 1995 - Present
Outstanding Teaching Award (Housestaff) 1995, 1996
The Laureate Award, Utah Chapter, American College of Physicians, 1997
America's Top Doctors 2001

V. ADMINISTRATIVE EXPERIENCE

Chief, Division of Rheumatology, Department of Internal Medicine, University of Utah, Salt Lake City, UT, 1-1-90 to 1-1-99
Associate Chairman, Department of Internal Medicine, University of Utah, Salt Lake City, UT, 7-1-80 to 9-1-01
Program Director, Internal Medicine Training Program, Department of Internal Medicine, University of Utah, Salt Lake City, UT, 8-1-80 to 9-1-89; 7-1-97 to 9-1-01
Program Director, Rheumatology Fellowship, University of Utah, Salt Lake City, UT, 1990 to 1997, and 1999 to present.
Acting Chairman, Department of Internal Medicine, University of Utah, Salt Lake City, UT, 4-7-80 to 6-30-80; 1-1-89 to 12-31-89
Vice Chairman, Department of Internal Medicine, University of Utah, Salt Lake City, UT, 8-1-75 to 4-6-80
Associate Director for Clinical Studies, Cooperative Systematic Studies of Rheumatic Diseases, University of Utah, Salt Lake City, Utah, 1976 - 1993
Director, Cooperative Systematic Studies Of The Rheumatic Diseases, 1994-1997
U.S. Army, Chief, Department of Medicine, Irwin Army Hospital, Ft. Riley, KS, April 1975 - July 1975
Chief, General Medical Service, Irwin Army Hospital, Ft. Riley, KS, June 1974 - July 1975
Acting Chief, Department of Medicine, Irwin Army Hospital, Ft. Riley, KS, June 1974 - August 1974
Acting Chief, Department of Clinics, Irwin Army Hospital, Ft. Riley, KS, June 1974 - August 1974

VI. PROFESSIONAL AND COMMUNITY ACTIVITIES

Board of Directors, Utah Chapter, Arthritis Foundation, Salt Lake City, UT, 1975-1983
Executive Committee, Utah Chapter, Arthritis Foundation, Salt Lake City, UT, 1978-1979
First Vice President, Utah Chapter, Arthritis Foundation, Salt Lake City, UT,

1980-1982

Council of Western Region of American Rheumatism Association, 1984 - 1986

Reviewer

Arthritis and Rheumatism

Journal of Rheumatology

American Journal of Medicine

Annals of Internal Medicine

Annals of Rheumatic Diseases

British Journal of Rheumatology

Drug Investigation

Journal Musculoskeletal Medicine

Medical Letter

Scandinavian Journal of Rheumatology

Obstetrics and Gynecology American Family Physician

American Family Physician

Journal Applied Physiology

Letter, Top 10% of reviewers for Annals Internal Medicine, 1994,
1997,2000,2001

Member, Ad Hoc American College of Rheumatology Committee on Disease

Modifying Antirheumatic Drugs, 1985

Consultant, Canadian Multicenter Cyclosporin Study, Safety Committee

Chairman, RA Treatment Subcommittee, Program Selection Committee,

American College of Rheumatology, 1990

Member, Abstracts Selection Subcommittee, 1982, 1987, 1990, 1991, 1992,
1993, 1994

Delegate, Utah Medical Association House of Delegates, 1996-present

Member, Task Force on National Research Plan, NIAMS, 1991

Member, Clinical Sciences Grant Review Subcommittee, Arthritis Foundation,
1988-1990

Member, Clinical Science Study Section, Arthritis Foundation 1991 - 1993

Chairman, Concurrent Session, American College of Rheumatology annual
meetings (1990, 1991, 1992, 1993, 1994)

Member, American College of Rheumatology, Outcome Measures
Subcommittee, 1991-1994

Member, International League Against Rheumatism, Outcome Measures
Subcommittee, 1992-1994

Contributor, ABIM subspecialty Recertification Examination, 1993; 1991; 1996;
1996

Editorial Board, Arthritis and Rheumatism, 1993 - 1997

Course Director, Utah State Medical Association Scientific Program, 1997

Program Chairman, American College of Physicians, Utah Chapter Regional
Meeting, 1982

Reviewer, Small Grant Applications, National Institutes of Health, 1999 - present

Chair, Students' Committee, American College of Physicians, Utah Chapter,
1995 - 1998

Visiting Professor and Glenn N. Clark Memorial Lecturer. University of Tennessee, Memphis. May 14-15, 1996.
Advisory Board, Center for Clinical Studies, 1996 – 1999
Member, Utah State Legislative Subcommittee on Finances for Graduate Medical Education, 1999-present.
Study Section, NIAMS, 1999
Study Section, NIAMS, 2000
Arthritis Advisory Committee, FDA 2000-present.
Governor-Elect Utah Chapter ACP-ASIM 2001
Governor, Utah Chapter, ACP-ASIM 2001 to present
Chairman DSMB CII Oral Tolerance in RA Patients off NSAIDs Trial – Univ Tenn 1999-present
Chairman-DSMB Phase B Trial of Oral Type 1 Bovine Collagen in Scleroderma- Univ Tenn 2000-present
Research Subjects Advocate, GCRC 2001 to present
Reviewer-American Pain Society Guidelines 2001
Special Panel, NIAMS, 2002

VII. UNIVERSITY COMMUNITY ACTIVITIES

Member, Department Executive committee, 1980 - 2001
Member, Medical Board, University of Utah, Salt Lake City, UT, November 1980 - 1996
Member, Clinical Sciences Council, University of Utah, Salt Lake City, UT, November 1980 - 1996
Member, University Gerontology Committee, University of Utah, Salt Lake City, UT, October 1980 - June 1981
Chairman, Malpractice Loss Control Committee, University of Utah, Salt Lake City, UT, July 1977 - July 1980. Member 1980 - 1985.
Chairman, Department Senior Electives Committee, University of Utah, Salt Lake City, UT, July 1976 - January 1981
Director, Department Senior Electives, University of Utah, Salt Lake City, Utah, 1981 - 2001
Member, Department Advisory Committee, University of Utah, Salt Lake City, UT, August 1975 - July 1980
Counselor, Utah Chapter, Alpha Omega Alpha, University of Utah, Salt Lake City, UT, April 1978 - 1989
Chairman, Department Teaching Committee, University of Utah, Salt Lake City, UT, July 1978 - June 1980
Member, Department Teaching Committee, University of Utah, Salt Lake City, UT, August 1975 - June 1978
Chairman, Ward Medicine Committee, University of Utah, Salt Lake City, UT, January 1980 - December 1980

Chairman, Ad Hoc Committee on Medications, 1982
Member, University Hospital Committee on Sports Medicine and Wellness, 1984
Chairman, Ad Hoc Committee on Reorganization of Dean's Office, January
1985-April 1985
Member, Hospital and Physicians Billing Committee, 1984 - 1986
Member, Committee on Clinical Tract, January 1985 - July 1985
Chairman, Ob Gyn Departmental Review, 1989
Member, Department Housestaff Committee, 1989 - 2001
Member, School 4th Year Curriculum Committee, 1990 - 2001
Member, School Appointments Committee, 1992 - 2001
Member, Awards Committee, Utah Chapter ACP-ASIM, 2000
Member, Pastoral Care Committee, 1994-present
Member, Risk Management Committee, 1995-present
Member, Patient Satisfaction Committee, 1996-1999
Member, Department Education Committee, 1996-1999
Member, University RPT Standards and Appeals Committee, 2000-2003
Member, University Conflicts of Interest Committee, 2001-present
Member, Search Committee, Chair of Physical Medicine and Rehab, 2000-2001

VIII. MEMBERSHIP IN PROFESSIONAL SOCIETIES

Diplomate American Board of Medical Examiners, 1970
Diplomate American Board of Internal Medicine, 1972
Diplomate American Board of Internal Medicine, Rheumatology, 1978
Salt Lake County Medical Society, 1975-present
Utah Medical Association, 1975-present
Fellow, American College of Physicians, 1981
Fellow, American College of Rheumatology, 1986

IX. PUBLICATIONS

Articles

1. Williams HJ, Biddulph CE, Coleman SS, Ward JR: Isolated rheumatoid nodules (pseudorheumatoid). J Bone Joint Surg 1977; 59A:73-76.
2. Williams HJ, Samuelson CO, Zone JJ: Nodular panniculitis associated with jejuno-ileal bypass surgery. Arch Dermatol 1979; 115: 1091-1093.
3. Samuelson CO, Williams HJ: Ibuprofen associated aseptic meningitis in systemic lupus erythematosus. Western J Medicine 1979; 131:57-59.
4. Samuelson CO, Cockayne TW, Williams HJ: Rheumatology: what should students know? Arthritis Rheum 1979; 22: 290-293.

5. Cheng DS, Williams HJ, Kitahara M: Hereditary hepatosplenomegaly. *Western J Medicine* 1980; 132:70-74.
6. Williams HJ, Klauber MR, O'Brien WM, Ward JR: A comparison of high and low dose cyclophosphamide therapy in rheumatoid arthritis. *Arthritis Rheum* 1980; 23:521-527.
7. Clegg DO, Samuelson CO, Williams HJ, Ward JR: Articular complications of jejunio-ileal bypass surgery. *J Rheumatol* 1980; 7:65-70.
8. MacCarter DJ, Williams HJ, Samuelson KM, Samuelson CO: Localized nodular synovitis of the knee. *Orthopedics* 1980; 3:1102-1104.
9. Ward JR, Williams HJ: Interim observations on benefit/risk of azathioprine versus D-penicillamine in the treatment of rheumatoid arthritis. *Ann Rheum Dis* 1982; 41:23-25.
10. Ward JR, Williams HJ, Egger MJ et al, 1983: Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of progressive rheumatoid arthritis. Response by treatment duration. *Excerpta Medica, Amsterdam, Current Clinical Practice Series, Auranofin* 1982, p 115-134.
11. Ward JR, Williams HJ, Reading JC, Egger MJ: Evaluating slow - acting antirheumatic drug therapies for rheumatoid arthritis. *Clinical Rheum* 1983; 2:189 - 195.
12. Williams HJ, Ward JR et al, for the Cooperative Systematic Studies of Rheumatic Diseases. Low-dose D-penicillamine therapy in rheumatoid arthritis: a controlled, double-blind clinical trial. *Arthritis Rheum* 1983; 26:581-592.
13. Egger MJ, Ward JR, Reading JC, Williams HJ, Wise G: Methodological advantages of multi-institutional studies. *Proceedings NIH Conference on Arthritis Epidemiology. Monograph*, 1983.
14. Ward JR, Williams HJ et al, for the Cooperative Systematic Studies of Rheumatic Diseases. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of progressive rheumatoid arthritis. A controlled clinical trial. *Arthritis Rheum* 1983; 26:1303-1315.
15. Williams HJ, Ward JR, Egger MJ, Reading JC et al: Comparison of oral and parenteral gold therapy and placebo in the treatment of rheumatoid arthritis. *Scand J Rheum* 1983; 51 :92-99.

16. Ward JR, Williams HJ, Egger MJ et al: Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. Subsets of responses. *Am J Med* 1983; 75:133-137.
17. Williams HJ, Reading JC, Ward JR: Design and analysis of controlled clinical trials in rheumatic diseases. In: Eds. Klippel JH, Decker JL, *Clinics in Rheumatic Diseases*, Vol 9, WB Saunders Co, Ltd, London 1983; pp 499-514.
18. Williams HJ, Ward JR, Egger MJ et al: Auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatic diseases. *Clinical Rheum* 1984; 3:39-50.
19. Wilkens RF, Williams HJ, Ward JR et al: Randomized, double-blind, placebo controlled trial of low dose pulse methotrexate in psoriatic arthritis. *Arthritis Rheum* 1984; 27:376-381.
20. Paulus HE, Williams HJ, Ward JR et al: Azathioprine versus D - penicillamine in rheumatoid arthritis in patients who have failed gold therapy. *Arthritis Rheum* 1984; 27:721-727.
21. Williams HJ, Wilkens RF, Samuelson CO Jr et al: Comparison of low dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. *Arthritis Rheum* 1985; 28:721-730.
22. Servilla KS, Green JA, Williams HJ, Zone JJ: An unusual systemic staphylococcal illness with features of the mucocutaneous lymph node syndrome. *Western J Med* 1985; 142:257-259.
23. Egger MJ, Huth DA, Ward JR, Reading JC, Williams HJ: Reduced joint counts in the evaluation of rheumatoid arthritis. *Arthritis Rheum* 1985; 28:613-619.
24. Egger MJ, Coleman ML, Ward JR, Reading JC, Williams HJ: Uses and abuses of analysis of covariance in clinical trials. *Controlled Clinical Trials* 1985; 6:12-24.
25. Williams HJ, Furst D, Dahl SL et al: Double-blind multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline in treatment of hand ulcers in patients with scleroderma. *Arthritis Rheum* 1985; 28:308--314.

26. Dahl SL, Coleman MI, Williams HJ: Lack of correlation between blood gold levels and clinical response in patients with definite or classical rheumatoid arthritis on two forms of gold therapy. *Arthritis Rheum* 1985; 28:1211-1218.
27. Williams HJ, Cannon GW, Ward JR: Methotrexate-induced pulmonary toxicity in patients with rheumatoid arthritis. *Rheumatol* 1985; 9:244-251.
28. Williams HJ, Ward JR, Samuelson CO Jr et al: Methotrexate and placebo therapy in rheumatoid arthritis. *Rheumatol* 1985; 9:174-189.
29. Cannon GW, Jackson CG, Samuelson CO Jr, Ward JR, Williams HJ, Clegg DO: Chlorambucil therapy in rheumatoid arthritis: clinical experience in 28 patients and literature review. *Sem Arthritis Rheum* 1985; 15:106-118.
30. Zygmunt DJ, Williams HJ, Bienz SR: Acute pancreatitis in association with long term sulindac therapy. *Western J Med* 1985; 144:461-462.
31. Williams HJ, Ward JR, Reading JC: Letter to the Editor. Multi-clinic study of DMSO for systemic sclerosis. *Arthritis Rheum* 1985; 28:1437-1438.
32. Williams HJ, Ziter FA, Banta CA: Childhood eosinophilic fasciitis. Progression to linear scleroderma. *J Rheumatol* 1986; 13:961-962.
33. Cockayne TW, Williams HJ, Samuelson CO Jr: A ten year review of an internal medicine honors program for fourth-year students. *J Med Education* 1986; 61:848.
34. Williams HJ: Methotrexate for severe RA: How safe? And for how long? *J Musculoskel Med* 1986; 3:9.
35. Weinstein A, Rothfield NF, Williams HJ et al: Lack of induction of antinuclear antibodies by D-penicillamine in rheumatoid arthritis: a controlled study. *J Rheumatol* 1986; 13(2):308-311.
36. Williams HJ, Dahl SL, Swanson HJ et al: Toxicity of long term low - dose D-penicillamine therapy in rheumatoid arthritis. *J Rheumatol* 1987; 14:67-73.
37. Williams HJ: Toxicity of low-dose pulse methotrexate in the treatment of rheumatoid arthritis. *J Med Consultation* 1987; 27:151-152.
38. Mathews JL, Williams HJ: Arthritis in hereditary hemochromatosis. *Arthritis Rheum* 1987; 30:1137-1141.

39. Williams HJ, Dahl SL, Ward JR et al: One year experience in patients treated with auranofin following completion of parallel controlled trial comparing auranofin, gold sodium thiomalate, and placebo. *Arthritis Rheum* 1988; 31:9-14.
40. Williams HJ: Comparison of sulfasalazine to gold and placebo in the treatment of rheumatoid arthritis. *J Rheumatol* 1988; 15:9-13.
41. Moncur C, Williams HJ: Cervical spine pain management in patients with rheumatoid arthritis: a review of the literature. *Phys Therapy Practice* 1988; 68:509-515.
42. Williams HJ, Ward JR, Dahl SL, Clegg DO et al: A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. *Arthritis Rheum* 1988; 31: 702-713.
43. Fuller JD, Williams HJ, McRorie TI: Necrotic bilateral hip ulcerations occurring two years after last multiple intramuscular iron dextran injections. *Arch Dermatol* 1988; 124:1722-1723.
44. Fehlauser CS, Carson CW, Cannon GW, Ward JR, Samuelson CO, Williams HJ, Clegg DO: Methotrexate therapy in rheumatoid arthritis: two year follow-up study. *J Rheumatol* 1989; 16:307-312.
45. Williams HJ: Gynecomastia as a complication of auranofin therapy. *J Rheumatol* 1989; 15:1863-1864.
46. Shirley HH, Lundergan MK, Williams HJ, Spruance SL. Lack of ocular changes with dimethyl sulfoxide therapy of scleroderma. *Pharmacotherapy* 1989; 9(3) :165-168.
47. Anderson JJ, Felson DT, Meenan RF, Williams HJ: Which traditional measures should be used in rheumatoid arthritis clinical trials? *Arthritis Rheum* 1989; 32:1093-1099.
48. Williams HJ: Future prospects for treatment of rheumatoid arthritis. *Current Opinion Rheumatol* 1989; 1: 52-57.
49. Ward JR, Egger MJ, Reading JC, Williams HJ: (Letter) Categorizing patients with gold dermatitis as "treatment failures." *Arthritis Rheum* 1989; 32:508.

50. Williams HJ: Intrasynovial methotrexate? (Comment and consultation). Consultant 1989; 29:19.
51. Williams HJ: Brief prednisone therapy: How much risk of osteonecrosis? (Comment and consultation.) Consultant 1989; 29:18.
52. Tugwell P, Bombardier C, Buchanan WW, Williams HJ et al: Methotrexate in rheumatoid arthritis: impact of methotrexate upon quality of life in rheumatoid arthritis assessed by traditional health status and patient preference questionnaires. Arch Int Med 1990; 150:59-62.
53. Williams HJ, Clegg DO: Basic therapy of rheumatoid arthritis: nonsteroidal anti-inflammatory drugs. Comprehensive Therapy 1990; 16(5):58-64.
54. Dahl SL, Samuelson CO Jr, Williams HJ, Ward JR, Karg MC: Second line antirheumatic drugs in the elderly with rheumatoid arthritis: a post hoc analysis of three controlled trials. Pharmacotherapy 1990; 10:79-84.
55. Paulus HE, Egger MJ, Ward JR, Williams HJ: Analysis of improvement in individual rheumatoid arthritis patients treated with disease modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990; 33:477-484.
56. Alarcon GS, Schrohenloher RE, Bartolucci AA, Ward JR, Williams HJ, Koopman WJ: Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum 1990; 33:1156-1161.
57. Odell WD, Williams HJ, Stults BM: Planning parenteral leave. Ann Int Med 1990; 112:553.
58. Williams HJ: Monitoring methotrexate for rheumatoid arthritis. (Comment and consultation). Consultant 1990; 30:16.
59. Williams HJ: Methods of clinical measurement. Current Opinion in Rheumatology 1990; 2:309-315.
60. Moncur C, Williams HJ: Physical therapy management of patients with rheumatoid arthritis. Physical Rehab Med 1990; 2:11-24.
61. Williams HJ: Approaches to the therapy of rheumatoid arthritis. Clinical Immunol Newsitr 1990; 10:144-147.

62. Alarcon GS, Williams GV, Singer JZ, Steen VD, Clegg DO, Paulus HE, Billingsley LM, Luggen ME, Polisson RP, Wilikens RF, Yarboro C, Karg MB, Thorderson LG, Egger MJ, Williams HJ, Ward JR: Early undifferentiated connective tissue disease. I. Early clinical manifestations in a large cohort of patients with undifferentiated connective tissue diseases. Compared with cohorts of well established connective tissue disease. *J Rheumatol* 1991; 18:1332-1339.
63. Clegg DO, Williams HJ, Singer JZ, et al: Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. *J Rheumatol* 1991; 18:1340-1343.
64. Paulus HE, Egger MJ, Ward JR, Williams HJ: Composite index methodology: Reply to Letter to the Editor. *Arthritis Rheum* 1991; 34: 502-504.
65. Williams HJ: Isolated calcaneal metastasis in a patient with endometrial adenocarcinoma. *Cancer* 1991; 67:1979-1983.
66. Williams HJ, Ward JR, Clegg DO, et al, for the Cooperative Systematic Studies of Rheumatic Diseases. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. *Arthritis Rheum* 1992; 35:259-269.
67. Williams HJ: Comparison of auranofin, methotrexate and the combination of both in the treatment of rheumatoid arthritis. Reply to Letter to the Editor by Drs. Epstein and Criswell. *Arthritis Rheum* 1992, 35:1407.
68. Jackson CG, Williams HJ: Current method of management of rheumatoid arthritis. *Comprehensive Ther* 1993; 18:(12):3-7.
69. Bulpitt KJ, Clements PJ, Lachenbruch PA, Paulus HE, Peter JB, Agopian MS, Singer JZ, Steen VD, Clegg DO, Ziminski C, Alarcon GS, Luggen ME, Polisson RP, Wilikens RF, Williams HJ, Ward JR: Early undifferentiated connective tissue disease. III. Outcome and prognostic indicators in early systemic sclerosis. *Ann Int Med* 1993; 118: 602-609.
70. Felson D, Anderson J, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, Paulus H, Tugwell P, Weinblatt M, Widmark R, Williams HJ, Wolfe F: American College of Rheumatology core set of disease activity measures for use in rheumatoid arthritis clinical trials. *American College of Rheumatology*, 1993; *Arthritis Rheum* 1993; 36: 729-740.

71. Williams HJ, Egger MJ, Clegg DO, et al: Comparison of naproxen and acetaminophen in the treatment of osteoarthritis of the knees. *Arthritis Rheum* 1993; 36:1196-1206.
72. Williams HJ: Clinical trials in rheumatology. *Current Opinion in Rheumatology*, 1993; 5:146-152.
73. Pun YL, Moskowitz RW, Lie S, Sundstrom WR, Block SR, McEwen C, Williams HJ et al: Clinical correlations of osteoarthritis associated with a single-base mutation (arginine⁵¹⁹ to cysteine) in type II procollagen gene: a newly defined pathogenesis. *Arthritis & Rheum* 1994; 37:264-269.
74. Kremer JM, Alarcon GS, Lightfoot RW Jr., Wilkens RF, Furst DE, Williams HJ, Dent PB, Weinblatt ME. Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity. *Arthritis Rheum* 1994; 37:316-328.
75. Clague RB, Morgan K, Reynolds I, Williams HJ: Serum IgG antibodies to type II collagen in American patients with rheumatoid arthritis. *Brit J Rheum* 1994; 33:336-338.
76. Apfelbaum JD, Williams HJ: Case report: Factitious simulation of systemic lupus erythematosus with hematuria. *West J Med* 1994; 160:259-261.
77. Williams HJ, Egger ME, Singer JZ et al: Comparison of hydroxychloroquine and placebo in the treatment of arthropathy of systemic lupus erythematosus. *J Rheumatol* 1994; 21:1457-1462.
78. Williams, HJ, Ward, JR: Letter to the editor. *Arthritis Rheum* 1994; 37:963.
79. American College of Rheumatology Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials (Felson D, Anderson J, Boers M, Bombardier C, Furst D, Goldsmith C, Lightfoot R Jr, Paulus H, Tugwell P, Weinblatt M, Katz L, Williams HJ, Wolfe F): Reduced joints counts in rheumatoid arthritis clinical trials. *Arthritis Rheum* 1994; 37:463-464.
80. Williams HJ: Combination second - line therapy for rheumatoid arthritis. Editorial *Brit J Rheumatol* 1994; 33:603-604.
81. Egger MJ, Ward JR, Karg MB, Williams HJ, Reading JC: Reliability and vailidity of the CSSRD functional assessment survey in rheumatoid arthritis. *Arthritis Care & Res*; 1995; 8:21-27.

82. Shaskey DJ, Sawitzke AD, Mijer J, Williams HJ: Subdural fluid collections: an unusual manifestation of CNS disease in a overlap syndrome of SLE and scleroderma. *Clinical Rheum* 1995; 14:1-4.
83. Rheumatoid Arthritis Clinical Trial Archive Group (RACTAG) (Felson DT, Chernoff M, Anderson JJ, Weinblatt M, Furst D, Schmidt F, Williams HJ, Wilke W, Suarez-Almazor M, McKendry R, Bell M). The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. *J Rheumatol* 1995;22:218-223.
84. Calvo-Alen J, Alarcon GS, Burgard SL, Williams HJ: Predictors of renal involvement in patients with recent onset systemic lupus erythematosus. *Journal Clinical Rheumatology*, 1995; 1: 260-267.
85. Moncur C, Williams HJ: Rheumatoid arthritis: Status of drug therapies. *Physical Therapy*; 1995; 75:511-525.
86. Felson DT, Andersen JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, Tugwell P, Weinblatt M, Williams HJ, Wolfe F, Kieszak S. American College of Rheumatology preliminary definition of improvement in Rheumatoid Arthritis: *Arthritis Rheum*; 1995; 38:727-735.
87. Williams HJ: Overview of combination second line or disease modifying antirheumatic drugs therapy in rheumatoid arthritis. *Brit J Rheumatol*; 1995; 34 (Suppl. 2) :96-99.
88. Calvo-Alen J, Alarcon GS, Burgard SS, Burst N, Bartolucci A, Williams HJ: Systemic Lupus Erythematosus: Predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: Multivariate analyses and identification of risk factors. *J Rheum*, 1996; 23:469-475.
89. Alarcon GS, Willkens RF, Ward JR, et al: Early Undifferentiated Connective Tissue Disease IV. Musculoskeletal manifestations in a large cohort of patients with undifferentiated connective tissue diseases compared to cohorts of well established connective tissue diseases: Follow-up data analyses in patients with unexplained polyarthritis and rheumatoid arthritis at baseline. *Arthritis & Rheum*. 1996: 39:403-414.
90. Beasel JF, Holderbaum D, Mallock V, Haqqi TM, Williams HJ, Moskowitz RW: Hereditary osteoarthritis with mild spondyloepiphyseal dysplasia are there "hot spots" on COL2A1? *J. Rheum*, 1996; 23:1594-1598.

91. Williams HJ. Long-term therapy with acetaminophen in osteoarthritis. *Postgraduate Med* 1996; December:29-33.
92. Borigini MJ, Egger MJ, Williams HJ, Paulus HE, Ward JR. TJ-114 (Sairei-To), and herbal medicine in rheumatoid arthritis. A preliminary "go - no go" clinical trial. *J Clin Rheumatol* 1996; 2:309-316.
93. Williams HJ, Weisman MH, Berry CC. Breast implants in patients with differentiated and undifferentiated connective tissue disease. *Arthritis Rheum* 1997; 40(3):437-440.
94. Jones G, Crotty M, Brooks P and the Psoriatic Arthritis Meta-Analysis Study Group (Bengtsson M, Bengtsson U, Capell H, Carette S, Combe B, Farr M, Williams HJ, Dougados M). Psoriatic arthritis: a quantitative overview of therapeutic options. *Brit J Rheum*, 1997; 36:95-99.
95. Williams HJ. Tramadol Hydrochloride: Something new in oral and analgesic therapy. *Current Therapy Research*, 1997; 58:215-226.
96. Williams HJ, Alarcon GS, Neuner R, et al. Early Undifferentiated Connective Tissue Disease. V. An Inception Cohort Five Years Later: Disease Remissions and Changes in Diagnosis in Well Established and Undifferentiated Connective Tissue Diseases. 1998, *J Rheum*; 25(2):261-268.
97. Jackson CG, Williams HJ. Treating Progressive RA with Disease-Modifying Drugs. *IM Internal Medicine*, 1998; 19: 39-46.
98. Jackson CG, Williams HJ. Disease-Modifying Antirheumatic Drugs: Using Their Clinical Pharmacological Effects as a Guide to Their Selection. *Drugs*, 1998; 56: 337-344.
99. Williams HJ, Alarcon GS, Joks R, et al. Undifferentiated Connective Tissue Disease. VI An Inception Cohort After Ten Years: Disease Remissions and Changes in Diagnoses in Well-Established and Undifferentiated Connective Tissue Disease. *J Rheumatol* 1999;26:816-25.
100. Daoud KF, Jackson CG, Williams HJ. Basic Therapy for Rheumatoid Arthritis: Non-Steroidal Antiinflammatory Drugs. *Comprehensive Therapy* 1999; 25:427-433.

101. Berthelot JM, Klarlund M, McGonagle D..., Williams HJ, et al. Lessons from an International Survey of Paper Cases of 10 Real Patients From an Early Arthritis Clinic. J Rheumatol 2001; 28:975-981.
102. Albert DA, Huang G, Dubrow G, Brensinger C, Berlin J, Williams HJ. Criteria for Improvement in Rheumatoid Arthritis: Alternatives to the ACR-20 (Submitted)

Books

1. (Eds) Van de putte LBA, Furst DE, Williams HJ, vanReil PLCM: Therapy of Systemic Rheumatic Disorders. Marcel Dekker Inc, New York, 1997.

Book Chapters

1. Williams HJ, Ward JR: Musculoskeletal occupational syndromes. In: Ed. Rom WN, Environmental and Occupational Medicine, Little Brown and Co., 1983.
2. Egger MJ, Ward JR, Reading JC, Williams HJ, Wise G: Methodological advantages of multi-institutional studies. In: Eds. Lawrence RC and Shulman LE, Epidemiology of the Rheumatic Diseases, Gower Medical Publishing Ltd, NY, 1984.
3. Williams HJ: Antimalarials. In: Eds. Wilkens RF, Dahl SL, Therapeutic Controversies in the Rheumatic Diseases, Grune and Stratton Inc, NY, 1987, pp 193-212.
4. Williams HJ: Sulfasalazine in rheumatic disease. Proceedings of the International Rheumatology Conference. Toronto, Ontario, Canada, May 1987. Ed Kean WF, Medicopea, pp 17-24.
5. Cannon GW, Williams HJ: Pulmonary toxicity of methotrexate. In: Ed. Wilke WS, Methotrexate Therapy in Rheumatic Disease, Marcel Dekker Inc New York, 1989, pp 243-260.
6. Williams HJ, Ward JR: Methotrexate in combination with other disease modifying agents. In: Ed. Wilke WS, Methotrexate Therapy in Rheumatic Disease, Marcel Dekker Inc NY, 1989, pp 115-121.
7. Clegg DO, Williams HJ: Ankylosing spondylitis. In: Postgraduate Advances in Rheumatology 1990; Forum Medicum Inc.

8. Cannon GW, Williams HJ: Immunosuppressive agents: azathioprine, alkylating agents, and combination therapy. In: Eds. Furst D and Weinblatt M, Immunomodulators in the Rheumatic Diseases, Marcel Dekker Inc, New York, 1990; pp 23-59.
9. Williams HJ: Rheumatoid Arthritis, Treatment. In: Primer of the Rheumatic Diseases, 10th Edition. American College of Rheumatology. 1993, pp 96-99.
10. Williams HJ: Combination DMARD Therapy in Rheumatoid Arthritis, In: Eds. Van de Putte L, Furst DE, Williams HJ, Van Riel P, Therapy of Systemic Rheumatic Disorders, Marcel Dekker In New York, 1997, pp 245-261.
11. Battistone MJ, Williams HJ:: Combination Drug Therapy. In: Ed. Koupman WJ, Arthritis and Allied Conditions – a Textbook of Rheumatology, 14th edition 2001, pp 814 – 826.
12. Battistone MJ, Williams HJ: Methotrexate. In: Eds. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH., Rheumatology, Third edition (in press).

Book Reviews

1. Williams HJ. Betrayal by the Brain: The Neurologic Basis of Chronic Fatigue Syndrome, Fibromyalgia Syndrome and Related Neural network Disorders and a Companion Volume to Dr. Jay A. Goldstein's Betrayal By the Brain. A Guide for Patients and Their Physicians. J. Pharmaceutical Care in Pain and Symptom Control. 1997; 5:115-116.
2. Williams HJ. Controversies in Fibromyalgia and Related Conditions. Rheum Dis. Cl. North America. J. Pharmaceutical Care in Pain and Symptom Control. 1997; 5:82-83.

Abstracts

1. Samuelson CO, Clegg DO, Williams HJ, Ward JR, Hill HR: Arthritis following jejuno-ileal bypass: a possible role for group D streptococci. Clinical Research 1977; 25:366A.
2. Williams HJ, Christensen WR, Samuelson CO, Ward JR: Hereditary multiple chondrospndyloepiphyseal dysplasia. XIV International Congress of Rheumatology, San Francisco, 1977; p 59.

3. Shields MN, Williams HJ, Samuelson CO, Ward JR: Subtalar splints in the treatment of pronation of the foot. XIV International Congress of Rheumatology, San Francisco, 1977; p 106.
4. Williams HJ, Klauber MR, O'Brien WM, Ward JR: A comparison of high and low dose cyclophosphamide therapy in rheumatoid arthritis. *Clinical Pharmacology & Therapeutics* 1979; 25:253.
5. Williams HJ for the Cooperating Clinics for the Systematic Studies of Rheumatic Diseases. Low dose D-penicillamine therapy in rheumatoid arthritis. *Arthritis Rheum* 1980; 23:764.
6. Egger MJ, Reading JC, Ward JR, Williams HJ, Chiu GL: Variable dose strategies: advantages and disadvantages. 1981 Joint Statistical Meetings, Detroit MI.
7. Egger MJ, Ward JR, Reading JC, Williams HJ, Coleman ML: Evaluation of summary indices of response in controlled clinical trials. *Controlled Clinical Trials* 1982; 3:154.
8. Williams HJ for the Cooperative Systematic Studies of Rheumatic Diseases. A controlled clinical trial of auranofin, gold sodium thiomalate, and placebo in rheumatoid arthritis. VIII Pan American Congress of Rheumatology, Washington D.C. *Arthritis Rheum* 1982; 25 :S68.
9. Williams HJ for the Cooperative Systematic Studies of Rheumatic Diseases. Azathioprine versus D - penicillamine in rheumatoid arthritis patients who have failed gold therapy. American Rheumatism Association annual scientific meeting, San Antonio, TX, 1983. *Arthritis Rheum* 26:Suppl S9.
10. Mathews JL, Williams HJ: Arthritis in familial hemochromatosis. American Rheumatism Association annual scientific meeting, San Antonio, TX, 1983. *Arthritis Rheum* 26:Suppl S59.
11. Dahl SL, Ward JR, Williams HJ: Lack of correlation between blood gold levels and clinical response in patients with definite or classical rheumatoid arthritis on two forms of gold therapy. *Drug Intel* 1983; 17(6):449.
12. Williams HJ for the Cooperative Systematic Studies of Rheumatic Diseases. Azathioprine versus D-penicillamine in rheumatoid arthritis. Contact Associated International Ltd, NY, *Arthritis Meeting Reporter*, 1983.

13. Williams HJ for the Cooperative Systematic Studies of Rheumatic Diseases. Topical dimethyl sulfoxide in the treatment of digital ulcers in progressive systemic sclerosis. American Rheumatism Association, June 1984.
14. Jackson CG, Cannon GW, Clegg DO, Samuelson CO, Williams HJ, Ward JR: Hematologic toxicity and malignancy complicating chlorambucil treatment in rheumatoid arthritis. *Arthritis Rheum* 1984; 27:S59.
15. Williams HJ, for the Cooperative Systematic Studies of Rheumatic Diseases. Effect of increasing dose of methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum* 1985; 28:S87.
16. Dahl SL, Williams HJ: One year experience in patients treated with auranofin following completion of a trial comparing auranofin, gold sodium thiomalate, and placebo. *Arthritis Rheum* 1985; 28:S61.
17. Williams HJ, for the Cooperative Systematic Studies of Rheumatic Diseases. Comparison of sulfasalazine and gold sodium thiomalate in the treatment of rheumatoid arthritis. *Arthritis Rheum* 1987; 30:S60.
18. Dahl SL, Samuelson CO, Williams HJ: Slow acting antirheumatic drugs in the treatment of elderly patients with rheumatoid arthritis. American Rheumatism Association 52nd annual scientific meeting, Houston, TX, May 1988.
19. Williams HJ, Egger MJ, Ward JR, Reading JC: "Treated patient" analysis in controlled studies of rheumatoid arthritis. American Rheumatism Association 52nd annual scientific meeting, Houston, TX, May 1988.
20. Clegg DO, Williams HJ, for the Cooperative Systematic Studies of the Rheumatic Diseases: The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. 54th annual scientific meeting, American College of Rheumatology, Seattle, WA, 1990.
21. Williams HJ, Ward JR, Reading JC, for the Cooperative Systematic Studies of the Rheumatic Diseases: Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. 54th annual scientific meeting, American College of Rheumatology, Seattle, WA, 1990.
22. Clegg DO, Williams HJ: The prevalence of evaluating antinuclear antibodies in patients with rheumatic disease of less than one year

- duration. Western Region Meeting, American College of Rheumatology, Santa Barbara, CA, 1991.
23. Williams HJ, for the Cooperative Systematic Studies of the Rheumatic Diseases: Comparison of naproxen and acetaminophen in the treatment of osteoarthritis of the knees. American College of Rheumatology, Boston, MA, November 1991. *Arthritis Rheum* 1991; 34 (Suppl.): S84.
 24. Williams HJ, for the Cooperative Systematic Studies of the Rheumatic Diseases: Comparison of hydroxychloroquine and placebo in the treatment of lupus arthritis. American College of Rheumatology, Boston, MA, November 1991. *Arthritis Rheum* 1991; 34 (Suppl. 1): S186.
 25. Alarcon GS, Williams HJ, Egger MJ, Ward JR: One year follow-up analysis of a large cohort of patients with early undifferentiated connective tissue disease. American College of Rheumatology, Boston, MA, November 1991. *Arthritis Rheum* 1991; 34 (Suppl. 1) S150.
 26. Sawitzke AD, Jackson CG, Lundberg ML, Clegg DO, Williams HJ, Tolman KG, Ward JA: Serial liver biopsies from methotrexate treated rheumatoid arthritis patients. American College of Rheumatology, Boston, MA, November 1991. *Arthritis Rheum* 1991; 34 (Suppl 1): S160
 27. Williams HJ, for the Cooperative Systemic Studies of Rheumatic Diseases: Early connective tissue disease: Diagnosis after five years. 56th Annual Scientific Meeting, American College of Rheumatology, Atlanta, GA, October 11-15, 1992.
 28. Clegg DO, for the Aminobenzoate Study Group: Comparison of aminobenzoate and placebo in the treatment of scleroderma. 56th Annual Scientific Meeting, American College of Rheumatology, Atlanta, GA, October 11-15, 1992.
 29. Alarcon GS, Williams HJ, Ma KN, Egger M, Ward JR: Three - year follow - up analysis of a large cohort of patients with early undifferentiated connective tissue disease. 56th Annual Scientific Meeting, American College of Rheumatology, Atlanta GA October 11 - 15, 1992.
 30. Alarcon GS, Egger MJ, Williams HJ, Ward JR: Differential demographic and clinical features of patients with unexplained polyarthritis of less than 1 year symptom duration. 56th Annual Scientific Meeting, American College of Rheumatology, Atlanta, GA, October 11-15, 1992.

31. Kremer JM, Weinblatt ME, Williams HJ et al: Sensitivity and specificity of different liver function tests in monitoring MTX-treated RA patients over time. 57th Annual Scientific Meeting, American College of Rheumatology, San Antonio, TX, November 7 - 11, 1993.
32. Kremer JM, Weinblatt ME, Williams HJ et al: Elevations of AST and ALT, but not of alkaline phosphatase or bilirubin distinguished methotrexate vs auranofin in placebo treated rheumatoid arthritis patients. 57th Annual Scientific Meeting, American College of Rheumatology, San Antonio, TX, November 7-11, 1993.
33. Alarcon GS, Lightfoot RW, Williams HJ, Furst DE: Selective vs unselective liver biopsies in methotrexate-treated rheumatoid arthritis patients. 57th Annual Scientific Meeting, American College of Rheumatology, San Antonio, TX, November 7-11, 1993.
34. Jackson CG, Williams HJ: Frequency of rheumatologic complaints in the private practice of general internal medicine. 57th Annual Scientific Meeting, American College of Rheumatology, San Antonio, TX, November 7-11, 1993.
35. Jackson CG, Williams HJ: How accurate are general internists in diagnosing rheumatologic disease? 57th Annual Scientific Meeting, American College of Rheumatology, San Antonio, TX, November 7-11, 1993.
36. Williams HJ, Weisman MH: Silicone breast implants in patients with undifferentiated connective tissue disease. 58th Annual Scientific Meeting, American College of Rheumatology, Minneapolis, MN, October 23-27, 1994.
37. Jackson CG, Sawitzke AD, Clegg DO, Cannon GW, Tolman KG, Ward JR, Williams HJ: Monitoring methotrexate toxicity in rheumatoid arthritis: failure of ACR guidelines to predict hepatic fibrosis. 58th Annual Scientific Meeting, American College of Rheumatology, Minneapolis, MN, October 23-27, 1994.
38. Calvo-Alven J, Alarcon GS, Burgard SL, Bartolucci RA, Williams HJ: Progression to Systemic Lupus Erythematosus: A time dependent multivariate analysis of clinical and laboratory baseline features among patients with recent onset undifferentiated connective tissue disease (UCTD). 58th Annual Scientific Meeting, American College of Rheumatology, Minneapolis, MN, October 23-27, 1994.

39. Calvo-Alven J, Alarcon GS, Burgard SL, Bartolucci RA, Williams HJ: Baseline markers associated with lupus nephritis in patients with recent onset systemic lupus erythematosus. 58th Annual Scientific Meeting, American College of Rheumatology, Minneapolis, MN, October 23-27, 1994.
40. Sawitzke AD, Clegg DO, Williams HJ, Cannon GW, Tolman KG, Jackson CG. Serial liver biopsies in rheumatoid arthritis patients treated with methotrexate. 59th Annual Scientific Meeting, American College of Rheumatology, San Francisco, CA, October 21-26, 1995.
41. Williams HJ. Reexamination of a Trial Comparing Traditional Analysis of Multiple Variables, the Paulus Criteria, and the ACR Preliminary Definition of Improvement. 1998 National Scientific Meeting, American College of Rheumatology, San Diego, CA, November 8-23, 1998.